JPRN-jRCT2080220088未知2 期
A phase II confirmatory study of SMP-862 monotherapy in patients with type 2 diabetes mellitus
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Patients with type 2 diabetes mellitus who satisfy the following inclusion criteria
- •-Patients who are undergoing only diet and exercise therapies
- •-Patients whose HbA1c levels are 6.5% <= HbA1c < 12.0%, and are stable over 4 weeks
- •-Patients aged 20 to less than 75
- •-Outpatients
- •-Patients with hepatic dysfunction
- •-Patients with renal dysfunction
- •-Patients with severe cardiovascular or pulmonary dysfunction, patients who have other conditions which are likely to be associated with hypoxemia
- •-Patients with a history of lactic acidosis
- •-Patients who are dehydrated or patients who have severe gastrointestinal disorders such as diarrhoea or vomiting which are likely to cause dehydration
排除标准
- 未提供
研究者
相似试验
未知
2 期
A phase II confirmatory study of SMP-862 therapy in patients with type 2 diabetes mellitus who are concomitantly taking sulfonylureasJPRN-jRCT2080220089Dainippon Sumitomo Pharma Co., Ltd.
未知
2 期
ate phase II study on dose response of SMP-508 monotherapy in patients with type 2 diabetes mellitusType 2 diabetes mellitus patients whose blood glucose levels are not adequately controlled by diet and exercise therapiesJPRN-jRCT2080220179Dainippon Sumitomo Pharma Co., Ltd.
已完成
2 期
A phase 2 study of S-812217 in patients with major depressive disorderJPRN-jRCT2080225180SHIONOGI & CO., LTD.240
未知
3 期
ong-term study of SMP-862 in patients with paediatric type 2 diabetes mellitustype 2 diabetes mellitusJPRN-jRCT2080221475Dainippon Sumitomo Pharma Co., Ltd.40
未知
2 期
ate phase II study on dose response of SMP-508 therapy in patients with type 2 diabetes mellitus who are concomitantly taking alpha-glucosidase inhibitorType 2 diabetes mellitus patients whose blood glucose levels are not adequately controlled by alpha-glucosidase inhibitor in addition to diet and exercise therapiesJPRN-jRCT2080220292Dainippon Sumitomo Pharma Co., Ltd.